Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

UroGen Pharma (URGN) Gross Profit (2018 - 2025)

UroGen Pharma (URGN) has disclosed Gross Profit for 8 consecutive years, with $34.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Profit rose 56.37% year-over-year to $34.5 million, compared with a TTM value of $97.3 million through Dec 2025, up 19.41%, and an annual FY2025 reading of $97.3 million, up 19.41% over the prior year.
  • Gross Profit was $34.5 million for Q4 2025 at UroGen Pharma, up from $24.2 million in the prior quarter.
  • Across five years, Gross Profit topped out at $34.5 million in Q4 2025 and bottomed at $6.6 million in Q1 2021.
  • Average Gross Profit over 5 years is $17.6 million, with a median of $17.5 million recorded in 2024.
  • The sharpest move saw Gross Profit skyrocketed 220.65% in 2021, then grew 4.0% in 2024.
  • Year by year, Gross Profit stood at $14.6 million in 2021, then increased by 8.53% to $15.8 million in 2022, then skyrocketed by 34.21% to $21.2 million in 2023, then grew by 4.0% to $22.1 million in 2024, then skyrocketed by 56.37% to $34.5 million in 2025.
  • Business Quant data shows Gross Profit for URGN at $34.5 million in Q4 2025, $24.2 million in Q3 2025, and $20.7 million in Q2 2025.